-
-
- 2022-04-13
Fosun Diagnostics Receives China NMPA Approval for Its Independently Developed Novel Coronavirus Antigen Detection Kit Amidst of The National Efforts in Pandemic Prevention and Control
(13 April 2022, Shanghai, China) 13 April 2022, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma” or “the Group”; Stock Code: 600196.SH, 02196.HK) announced that the Novel Coronavirus (2019-nCoV) Antigen Detection Kit (Colloidal Gold) self-developed by Fosun Diagnostics Co., Ltd. (“‘Fosun Diagnostics”), a subsidiary company of Fosun
-
-
-
- 2021-11-25
Henlius Novel Anti-PD-L1/TIGIT Bispecific Antibody Receives Clinical Trial Approval in Australia
Shanghai, China, Nov, 24th, 2021 - Shanghai Henlius Biotech, Inc. (2696.HK) announced that the filing of a clinical trial for HLX301, a Recombinant Humanized Anti-PDL1 and Anti-TIGIT Bispecific Antibody
-
-
-
- 2021-11-12
Raw Materials and Preparations of Moxifloxacin Hydrochloride of Guilin Pharma Approved for Marketing and Passes Consistency Evaluation
On November 3, 2021, the raw materials and preparations (strength: 0.4 g) of moxifloxacin hydrochloride produced by Guilin Pharma were approved for marketing, which was deemed to have passed the consistency evaluation.
-
-
-
- 2021-11-09
Successful Completion of Phase I Clinical Trial of Pertuzumab Biosimilar HLX11 of Henlius
Shanghai, China, November 8th, 2021-Shanghai Henlius Biotech, Inc. (2696.HK) announced a phase 1 clinical trial of the company’s pertuzumab biosimilar HLX11, a recombinant anti-human epidermal growth factor receptor 2 (HER2) subdomain II humanized monoclonal antibody injection
-
-
-
- 2021-10-13
First Subject Dosed in Phase I Clinical Trial of Henlius Novel Monoclonal Antibody HLX26, Inhibitor of New Generation of Immune Checkpoint LAG-3
Shanghai, China, October 12th, 2021 – Shanghai Henlius Biotech, Inc. (2696.HK) announced that the first subject has been dosed with HLX26 (recombinant anti-LAG-3 human monoclonal antibody injection) for the Phase 1 clinical trial in patients with advanced/metastatic solid tumours or lymphomas.
-
-
-
- 2021-09-14
Yi Bao (Human Erythropoietin for Injection) for Cancer-related Anemia Indication Officially Approved
On September 14, 2021, Wanbang Biopharma announced that the new indication of Yi Bao (Human Erythropoietin for Injection) was recently officially approved by the National Medical Products Administration (NMPA) for the treatment of anemia caused by chemotherapy in patients with non-myeloid malignancies.
-
-
-
- 2021-08-18
HAN QU YOU® (60 mg/bottle) Officially Approved for Marketing for More Flexible Medication
On August 17, 2021, Henlius (2696. HK) announced that the Company had recently received the Approval Letter of Supplementary Application issued by the National Medical Products Administration (NMPA): HAN QU YOU® (trastuzumab, Zercepac in the EU) was formally approved by the NMPA for the sNDA of new strength (60 mg/vial, free of preservatives). After adding a new strength of 60 mg/vial in China, patients can use different strengths of HAN QU YOU® for more flexible medication.
-
-
-
- 2021-08-17
Axicabtagene Ciloleucel of Fosun Kite Included in the Breakthrough Therapeutic Drug Program
Fosun Kite Biotechnology Co., Ltd. announced today that the National Medical Products Administration (NMPA) has officially included the new indication of Axicabtagene Ciloleucel, a CD19-targeted autologous CAR-T cell therapy product of Fosun Kite, into the Breakthrough Therapy Designation (BTD) for the treatment of relapsed or refractory indolent non-Hodgkin's lymphoma (r/r iNHL), including follicular lymphoma (FL) and marginal zone lymphoma (MZL), after two or more lines of systemic therapy.
-
-
-
- 2021-06-28
Fosun Pharma: Second-generation TRK Inhibitor FCN-098 Clinically Approved
Recently, the Investigational New Drug Application (IND) was approved for FCN-098 capsules, a Class 1 new drug independently developed by Chongqing Fochon Pharmaceutical Research Co., Ltd. (hereinafter referred to as "Fochon Pharmaceuticals"). As a second-generation TRK inhibitor, FCN-098 is intended for the treatment of patients with advanced solid tumors with NTRK gene mutation.
-